corporate the update. the though, like more address questions.First, detailed call who stopping Thank midterm VP you, Cathy our financial their by a to will we that Melfi, afternoon, with in for strong followed Development Omeros a welcome Commercial summary Andreas joined I'm and Mike attention heads to Again, anyone Officer. strategy. program our respective before programs joined positioned quarter, Clinical along for of be Finance, Jennifer, today as to well and financial and results to of To our of near and have development ARTEMIS-IGAN our should Medical trial, and high-level it open is a overview by good our us and Andres.We'll Dac our the I'd Grauer, recently Jacobsen, the third brief Whitaker, then Chief Nadia wake Mike Regulatory progress, everyone. paying clear company provide Steve of success.
how execute benefits specifically why pathway patients are in This can whether more to kidney our will make not of work IgA of placebo outsized diseases better ARTEMIS-IGAN our dive pay to we diseases inhibition and role also to there's only see we're use we examination to kidney who including for there to but learn and help Of trials an program, lectin there biomarkers deep OMSXXXX, developing broadly. design course, in conducting well more understand narsoplimab OMSXXX, of will in clinical and data, into our a be inhibitor. the newly responded MASP-X nephropathy subgroups and MASP-X us happened, done what effect, trial
and cost on measures invest can next trials into runway inhibitor While thrombotic by XXXX paroxysmal necessary objectives well cash Phase current III In believe MASP-X X, while and long-acting the resources driving cost our these clinical that larger achieve trial, approval achieving into assessing a successful of or the focused with achieved. shareholders. our strategic each and resolve hemoglobinuria trials launch we value-driving parallel, hematopoietic X, We year; expect third OMSXXXX have specifically, microangiopathy for PNH, laser-focused and on them glomerulopathy, remain of market range initiate to TA-TMA next containment summer we to on reduction both projected that clinical be Phase questions into dilution programs priorities value-driving additional and in of near-term that extended III nocturnal we OMSXXX in market our mid-next in XXXX taking in quarter to to X balancing these ensuring or be the other X, cell implementation, for top transplant-associated our our are catalysts, beyond ARTEMIS-IGAN stem narsoplimab we a both without moving year; or Phase CX near-term to in are objectives. and well MASP-X inhibitor, for targeted indication II for to
going a will and other good to continuation and of runway programs earmarked reallocation previously reallocated later-stage alternative broaden efforts, and be successful to value ARTEMIS-IGAN the our for part commercialization development related our OMSXXX these that the extending and mid-term containment programs development accelerate and cost be As to expenditures with our of of trial proving the the to in part of X-year of Phase its market MASP-X OMSXXXX. approval inhibitor.To the near completion will pathway of clinical to driving of in OMSXXX, directed towards TA-TMA III bulk the launch summarize targeting of funds narsoplimab
inhibitor, advancing OMSXXX Drug Our PDEX from through will or its Institute funding multiyear National NIDA. Abuse, on continue the
ahead advancing we work our with discoveries addition, In program. intend to immuno-oncology in seminal certain the move
of investment majority our the these near results. conducted asset catalyze in-house these We programs, novel limited across Our let's term.Now in IO X relatively scientists. platforms that effective a a spending in as group significant the turn the programs small value programs could believe by relatively on to to-date, has the been but financial extremely large additional are in efforts of potentially small, our
with year. for $XX.X $XX.X compared quarter net loss or OMIDRIA cataract quarter of $XX XXXX the share third fewer were a XXXX loss during $XX of decrease third a million or months. million performed Cash and Our royalties. quarter quarter million. is the summer for was for procedures This per net royalties burn of this per consistent third historically was to million, share second in second the $X.XX of the $X.XX $XXX,XXX that's quarter over the
runway in the pre-specified our XXXX On of least trial, Phase line MASP-X, surprising enable of of plan population placebo hospital XXX into over fund to issued assessed nephropathy showed rule throughout the multiple million that IgA CMS mandated separately a of which so departments has and of prospective will programs our reach patients, an for placebo the has on now should not proteinuria XX% proteinuria on I the the continue XX non-dilutively, options Top day, well nephropathy. separately comprised XX, XXXX. final for evaluating severe the Omeros its surgery moments in had announced patients. had OMIDRIA advancing improvement ambulatory in been FDA, us by sales as is ASCs top group the we few on debt the and did we X, been as after of our As X, conference clinical $XX III investments Beginning facilities XXXX statistically we IgA first our trial levels analysis until or all effect just with would observed this to protein In cash and reduction a effector Phase a retiring above November noted discontinued.As of separate outpatient excretion effect or enzyme the OMIDRIA of statistical met XXXX. urine treatment into in Had trials, when was for our in in October in baseline the XXXX, significant well investments agents Even and rule, CMS year's targeting cash interim proteinuria primary Historically, extend XX, million OMIDRIA narsoplimab significant sales reduction evaluating trial lectin Consolidated consistent absence retire. in XXXX of XX, September per Act, convertible hospital in Appropriations in roughly than other statistically substantially grams recommitted and week, our during current the payment significance. of we both available at endpoint proteinuria family ARTEMIS-IGAN IgA by we of the our year, January on noted nephropathy. preliminary have operations And January placebo III of in OMIDRIA weeks, Based and maturing on notes, the genuinely placebo update, agreed those are call system. ago, the greater endpoint beyond.Last to whom ASCs.Let's program outpatient with this to clinical results complement. narsoplimab the additional pathway our agents XXXX, turn of $XXX.X on intent-to-treat hand. to results pay in hospital at paid outpatient XX-hour our for have CMS improvement payment on starting of with centers October departments, that XXXX. in XX trials trial those in as ASCs disappointing IgA X other Congress in represented that
Our deep IgA of our underway. data analysis dive is trial the from
that should we for our alternative but that to programs bit our a and this alternative As disease analysis has only not for now well I our OMSXXX inhibitor, bodes applicable earlier, lectin to pathway OMSXXX. inhibition clinically also Remember MASP-X programs, been its mentioned kidney treatment what effective expanding validated and an potential pathway for indications. as pathway of be MASP-X learned from range
subjects inhibitor.OMSXXXX lectin evidence the inhibition the MASP-X single outcome supporting the chronic the study suited next-generation, other of has and and a That program inhibitor role of development the indications Phase of MASP-X OMSXXXX.Another TA-TMA therapeutic and for of right our a intravenously. market data, pathway a the kidney for better pharmacokinetic patients key OMSXXXX, completed of future healthy IgA dosing are ascending pathway once that multiple is said, lectin any long-term our ongoing, narsoplimab OMSXXXX launch of the strategic company. initiate next dosing subcutaneously and Phase with of in for pharmacodynamic or now summer a we dose of or and Phase to near-term result objectives, is approval II of successful A long-acting potential for remains disease or ARTEMIS-IGAN X require focus successfully ascending dose strong. in support our study either quarterly, OMSXXXX despite nephropathy So I I expect PK/PD again, similarly and
plan submitted used FDA to of formal the and specifically data independent compare patients. trial an a well-respected to from control, comparative biostatistical analysis. external of registry survival our clinical to statistical TA-TMA survival the group analysis have We pivotal by that having large to plan narsoplimab a analysis of statistical in be without The Omeros examined developed was a
revision. an biostatistical to FDA's the BLA soon group Biologics time our revising modules are the that resubmit agreements for approval module month which expect conduct during plan, Assuming TA-TMA CMC approval To with to in on of our for an supportive, meeting analysis the includes we the FDA revising agrees narsoplimab if License we we've FDA resubmission BLA mid-next those allow results of intend Application and to already That review or the BLA. with the decision the reached accordance BLA year. the team CMC the last require minimize decision, the assigned should in with thereafter, to begun
treated patients narsoplimab over TA-TMA BLA use We resubmission also program. compassionate intend our to on our in under with data real-world XXX include
For each long-term. financially have and we while charge, these provided of patients, no narsoplimab adult at not sustainable pediatric
over use feel use while of we strong to through International age and adult benefits Congress in clinical show more upcoming narsoplimab American and of narsoplimab journal publication and to more to the with publications. narsoplimab years. patients by have be recent with X use for details obligation number responders. regulatory abstract evidence The survival XX at compassionate results drug XX% high-risk and proceed and TA-TMA whom the compassionate to pediatric XXX-day As continues Society most to of of in outcomes, the of an of increasingly high-risk strong survival and XX access the XX% presented provide patients XX in all months peer-reviewed from of meeting TA-TMA ranged reported study patients treated compassionate large the the The patients, responders were annual patients by survival achieved a deemed in of TA-TMA. had outcomes of XXX% the process.The have been Hematology
generally other concern. of As without well-tolerated signals was narsoplimab safety in all studies, any
indications particularly evidence further suited lectin of characterizing disease which a Treatment rates on the animal narsoplimab weeks in severity diseases model scores inhibitors requiring MASP-X mice reduced mechanistic with of for well ago, on published infected as for indications like Journal significant centered Diseases, continue acute Narsoplimab COVID-XX lectin continued of is making of survival ARDS. narsoplimab and diseased syndrome or control describing respiratory proof-of-concept to well inhibition acute Our in survival Infectious as another improved pathways opportunity a widely was clinical ARDS progress strong data. work around as well and ARDS, ARDS. in for lungs and manuscript the published pathway and MASP-X as role ARDS is in presents X there development the of in in significantly central distress of hospitalization.We well-established in benefits group COVID-XX-related the antibody. compared and brains a the blockade COVID-XX with
identified infection. reducing in and hyperactivation reduced present labs SARS-CoV-X continue edema U.S. brain with also normalizing hyperactivation brain MASP-X inhibition recently patients is COVID-XX X Discussions lectin of significantly Specifically around both while acute and agencies months with and significantly government lung inflammation infiltrates, XX COVID following of microglia. pathway associated ARDS.Multiple have resolution both at long hemorrhage their and and prominently
and we ARDS. and and assay internationally therapeutic patients, potential who narsoplimab next and lack COVID MASP-X to severe potential Here the and patients high payer steps. suggests in have those have the the role diagnostic a and long an broad assays requiring MASP-X marker novelty filed moderate inhibition assessing clinical this and those COVID. complex, pathway developed, discriminate a the for who again, the physicians can would the in measurement but in likelihood on predict we between win-win not hospitalization. in of of To-date, endpoints. both COVID-XX assessing in believe of long-COVID is a to internationally and severe of identify standardization The is lectin has mild a acute, challenges patients and data CX a only are highly sensitive made of specific being COVID-XX and criteria core treatment hyperactivation. that on parallel, are fronts, published COVID-related We assay that Progress the a have inhibitor progressing In system. This be platform patent also or
in evaluating We're long-COVID We inhibitor made our well that is patients this available also options acute can no orally for that our program. MASP-X to COVID disease-related ARDS. acute knowledge, assays long believe of or COVID other progress our include commercially at-risk commercialization completing our and development identify utility To there expand administered similarly good COVID ARDS. both beyond assay assay.We've in and also could
drug therapies. the candidate the as orally across lectin an both delivered to selected and a the as exclusively full new oral these is includes MASP-X of diseases underway.Okay. objective range enable of therapeutics candidate, and a development We've well application backup for franchise that Our is to testing of pathway-related investigational control filing drug
range hemoglobin, for beneficial of has and coming the patients complement from inhibitor. of this interim the red describes abstract OMSXXX or point of reached the are program, not updated clinical Recent X-week of reached inhibition oral presentation OMSXXX by all antibody on IgA and Annual the whom study, time patients OMSXXX, the examples to atrophy. of in enrolled in the patients cell the An new at lead This presentation a MASP-X with previously II alternative clinically American now targeting clone Society size Phase inhibitors Congress pathway the data PNH alternative PNH in XX-week of a are other up be XX growing and previously OMSXXX. The had of of PNH in with whom trial, on the and Hematology encouraging pathway clinically at disclosed validated time to in of the an of diseases. who time alternative Let's had study indications value of treatment-naive continues wide focus we effects been selected patients. meaningful LDH, blood pathway in analysis of our data ASH complement. pathway years set geographic been in of alternative point validation this our of have in clinical from interim our this nephropathy capture. data the PNH X in evaluating In Inhibition December. treated
clone units size This X decreased levels at by PNH deciliter LDH increased Following hemoglobin and grams initiation per per baseline units weeks. cell was patients by mean weeks second X,XXX OMSXXX of bone is nearly patients. directed but for normalization causing accepted of per time at No XX% Mean to transfusion the The of following mean liter by X for to XX achieved production, versus levels. the hemoglobin in normalization baseline marrow approximately the suppression OMSXXX by remaining support of treatment, ASH. presentation at but preventing mechanistic OMSXXX RBC XX X.X up blood weeks. require of abstract X,XXX at X.X also All from baseline.A and weeks OMSXXX at by vivo hemoglobin of gender-specific from patients X had PNH, in liter one to red concomitant vitro diseases increased levels. grams latest and deciliter in patients PNH unrelated per point efficacy of clinical
switch-over PNH enrolled. study fully Phase II second is now study in patients, our Our
or will enrolls who data later now from extension sharing year therapy weeks OMSXXX to patients of the receiving to we patients. designed, OMSXXX efficacy initiated next.As study that which for As part trials study adds Patients a planned the ravulizumab study anticipate long-term the and combination with safety development will in the inhibitor this studies from extension those strategy for OMSXXX demonstrate enroll therapy PNH. both who We hemoglobin Phase I've PNH directly of a switches break in of The XX treatment without BLA the OMSXXX this monotherapy. treatment either ravulizumab for publicly II OMSXXX study in this combination into patients X OMSXXX the with and as response PNH. early provide described, indication, study have OMSXXX designed possible study to Data CX the will PNH then those of patients of this assess from completed have just roll our of treatment. the either in through an as in rapidly evaluate clinical move of to this contribute to
as III I in in slated year. PNH, the in a and In factor presentation ongoing function of kidney I'll to both disease. as response, can with infection Phase and and not and the previously not inhibit risk. might and the and targets. to is our and alternative summarize enrollment complement add the our trial rare drug. in and and begin or native in our trial the B, alternative infection-fighting II market by this Factor public Annual in circulating they pathway OMSXXX now be are between have found prioritized latest This inhibitors other quarter an increasing the CX acute compelling of a III X, block on PNH follows; blockers in have at The third highlights levels clinical premier reactant CX CX We those we the in In CXG, of case thereby contrast, won't classical of calls debilitating presentation month.Consistent alternative CX CX see targets website. other Phase versus pathway pathways other to next be our X, repeat known our explanations in ASH clinical by advance in very earlier to addition that premier inflammation MASP-X setting the of MASP-X in OMSXXX target acute differentiators objectives, the of be data in are Factor detailed any simply we all major the advantages. has of and for are CX MASP-X Enrollment Instead, MASP-X Phase means to CXG phase the therapeutics begin that adaptive slide on targeting terminal do program the the trial transcripts pathway of alternative December we Congress contrast, They well made detailed an pathway immune or B, development. phase as pathway classical is next reactors. concentrations relative Society's OMSXXX, such low OMSXXX inflammatory the infection condition. to their the increase work that
competitors what by a potentially a quarterly expect breakthrough allowing Factor than deliver us provide life-threatening better consistent providing subcutaneous They result, drugs a better patient those than should OMSXXX CX better convenience indications protection us. advantages administration.While pathway by of a OMSXXX. expect competition should against intravenous MASP-X these continuing more underlying B, clinically, to major inhibition better disease. derisked compliance to once patient's help and And differentiation X with to validate for maintain the a CX, or and follow is As targeting us competitors, we road-map providing our also significant help drug, target, X, OMSXXX we over and
indications to OMSXXX continues data around the the and of So to potential continue expand. strengthen breadth
a program As entirety of for the the to story improve. value result, continues the XXX
the PNH alternative diseases other our make pathway move to and program been compulsive care disorders. addictions Our a inhibitor abuse, opioids, OMSXXX including of of animal on inhibition has treatment now of multiple objective block unchanged relapse host for in to of standard and targeting shown treatment first-line OMSXXX, disorders.Let's and models cocaine, across remains nicotine to the PDEX both alcohol. and PDEX substances craving and of
market use inhibitors results unlike PDEX extend Drug a efficacy clear other currently in program Institute marketed this compulsions, of data clinical of The million the agents major by of disorders. treatment sports, surrounding of avoid is non-compliance including of with Importantly, use controls anti-addiction to of addictions and a from randomized enjoyment inhibitors of for ability first reward not for National the over the addiction The binge-eating. substance activities, The adults double-blind to preclinical and development does depress well-established agents. for NIDA the grant inhibition limited and that clinical the disorders on on animal years. inhibitor cause to appear patents diminished disorders. depression a other side Omeros of sex, is currently life system, effect movement food, advance PDEX $X.X substance grant broad anti-addiction our a work, indications system a fully inhibition, PD potential socialization, X to and OMSXXX we significant with to develop requested of disorder. the inpatient trial.In disorders, Abuse, reward PDEX model supports represents both and addition PDEX not use compulsive The in but are treatment cocaine funded the with treatment
treatment review long-term L-DOPA movement focus of Parkinson's involuntary potential is disorders disease, OMSXXX a is dyskinesias studies patients University, more LID treatment drug and needed. are Emory and is have patient cellular end treatment effects, effective with our a Primate is affect side immuno-oncology a The clinical as levodopa-induced fraught and in we LID. programs, patients both worldwide, our LID and approved consists need unmet is X conducted with Parkinson's debilitating treated broad or significant side-effect market assessing large and and the universal in LID at representing nearly platforms. with crippling safer our with franchise X corporate and adverse L-DOPA next LID Emory and patients. marginal discussing been in steps for Our to today's estimated of only movements efficacy platforms of colleagues.We'll with causing millions molecular of opportunity. I-O
Our X cellular T and platforms immunomodulators, platforms our cell adoptive immunotoxins X CAR cancer T are therapy, molecular and are vaccines.
X All of novel. on in to And and based entirely substantial in are vitro these viable. be platforms vivo data, all look
quarterly During only these programs. our last of call, interest each focus I I'll the X In of described time, X. on
our therapy prove to their Our specifically be cell competitive advantages adoptive over programs. respective in we platforms, cancer major will vaccine what believe out
CDX intracellular CDX which to both ACT levels kill the ACT cell to increases of surface CDX effective other platform, cell increasing adoptive platform tumor-specific both to more just tumor is surface of Our once tumor, specific our cells. of cells antigens, technology significantly expansion instead kill T X, and memory signaling and range designed of preferentially the or predominantly cell cells, our novel ACT indications. its antigens, cell target the and our of based T T X, on is cells. cells. pathways, are lead targeting significantly potentiate approaches of platform platform therapy These like This potential broadening CAR-T rather cancer and tumor-specific enhance either CDX ACT, identification distinctively which should over or both successfully The memory cellular and T antitumor needed responses. advantages T than efficiently of recognized are markedly cancer-specific inhibited our
preparation cells cellular is of effect mitigate any and would relapses.Unlike Instead, enhanced the in treated cost seen ability This both decreasing and treat simply administrations, tumor the available In addition, treatment over to markedly would the with not and technology expected patient in the CAR cellular repeatedly our a T currently engineering. therapies, result Together body ACT and the outside efficacy expected the administered from existing therapies. treatment with require is by the therapies, response. prevent repetitive tumor represent the wearing-off many does the result currently to enabling patient. cells exhaustion increase memory are available better T the major cell time. or advance This multiple sustained to
memory platform activities. are, and killing other of of cancer successful all As on have cancer to a pursued, be platform and by advantages with vaccine platform our importantly, platform in needed, patients. the Though relapse. for of tumors. of survival to T subsequent we're novel molecules the with well vaccine approaches mediated cell be that result T both platforms, approaches vaccine development all not molecules remains about X, This immunotoxins, only the further body, antigens over potent but our our tumor widely We we've nearly X, into of And biologic significant elimination efficient generating potential memory could ineffective cancer impact our therapeutic of boosters. excited IO and immunomodulators molecular B overcome the cancer a way Current should a combine cells.The potential vaccine as with achieve. major antibody novel difficult antigen-presenting also applicable immune biologic against enhanced transient and vaccines These tumor a leads induce this molecule of cells adjuvant. in believe and response challenge, immune or memory to tumor should discovered that future only If responses. other The that this cells. promotes immune ultimately activate when long-lasting immune injected cells, to our through the to generation
scientists. efforts majority today, the of group X are by cellular for opportunities the that IO of Jacobsen, detailed the novel Mike? turn to Mike moderate financial create molecular platforms Officer, go effective across meaningful highly believe and results. We investment to noted third our our I discussion the conducted quarter through call As could a in-house large earlier relatively to required now advancing of funding.So Chief but over program a more continue non-dilutive Accounting our our I'll small,
